Fred R. Hirsch

Abstract: The inclusive and dijet production cross-sections have been measured for jets containing b-hadrons (b-jets) in proton–proton collisions at a centre-of-mass energy of √ s = 7 TeV, using the ATLAS detector at the LHC. The measurements use data corresponding to an integrated luminosity of 34 pb−1. The b-jets are identified using either a lifetime-based method, where secondary decay vertices of b-hadrons in jets are reconstructed using information from the tracking detectors, or a muon-based method where the presence of a muon is used to identify semileptonic decays of b-hadrons inside jets. The inclusive b-jet cross-section is measured as a function of transverse momentum in the range 20 < pT < 400 GeV and rapidity in the range |y| < 2.1. The bb-dijet cross-section is measured as a function of the dijet invariant mass in the range 110 < mjj < 760 GeV, the azimuthal angle difference between the two jets and the angular variable χ in two dijet mass regions. The results are compared with next-to-leading-order QCD predictions. Good agreement is observed between the measured crosssections and the predictions obtained using POWHEG + Pythia. MC@NLO + Herwig shows good agreement with the measured bb-dijet cross-section. However, it does not reproduce the measured inclusive cross-section well, particularly for central b-jets with large transverse momenta.

TL;DR: Plasma clearance of mutant EGFR ctDNA at 8-weeks was highly and significantly predictive of progression-free and overall survival, outperforming RECIST response for predicting long-term benefit.

TL;DR: Activating EGFR mutations correlate with increased 6 mo PFS probability in 1st line therapy in pts with chemonaive NSCLC and absence of KRAS mutation trend towards increased 6Mo PFS rate with E.

TL;DR: This phase II trial of E in unselected chemotherapy-naive pts with advanced NSCLC and PS 2 was performed to obtain preliminary data regarding efficacy and EGFR biology in this pt population, and to set the stage for a subsequent randomized Trial of E vs.chemotherapy, in pts selected for EGFR expression.

TL;DR: Based on a meta-analysis using two phase III, placebo-controlled trials of erlotinib, EGFR mutation testing, while of value in the first-line setting, should not be used to positively or negatively select patients for maintenance/second-line erlot inib.